Hongyi Zou

Hongyi Zou

Auto-generated profile, based on publicly available information

Hongyi Zou

Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15213, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
RSRoisin M. Sabol
Roisin M. Sabol
CSChristina N. Sun
Christina N. Sun
CGCasey A. Gudenburr
Casey A. Gudenburr
HZHongyi Zou
Hongyi Zou
TFTanya J. Fabian
Tanya J. Fabian
YXYing Xue
Ying Xue

25 August 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
CJChen Jiang
Chen Jiang
JQJunnan Qi
Junnan Qi
HZHongyi Zou
Hongyi Zou
OLOscar Lopez
Oscar Lopez
XXXiang-Qun Xie
Xiang-Qun Xie
YXYing Xue
Ying Xue
Background: Several hypotheses suggest that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD), and antidiabetic medications may influence cognitive function in these patients. Objective: This study aims to provide a comprehensive evaluation of the impact of single and combination antidiabetic therapies on cognitive function in patients with both AD and T2DM. Methods: We analyzed data from the National Alzheimer's Coordinating Center (NACC), covering a 17-year period from June 2005 to August 2022. This study included 3234 patients with both AD and T2DM. After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model. Patients were categorized based on their longitudinal use of oral antidiabetic medications. Results: Based on the 964 patients’ cohort, the study found that patients receiving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with a dipeptidyl peptidase 4 inhibitor (DPP-4i) (RR = 1.132 [1.021, 1.256], p = 0.019) experienced a significantly slower decline in MMSE scores over time when compared to patients receiving metformin with thiazolidinediones (TZD). Conclusions: This study demonstrates that combination therapies involving metformin with sulfonylureas or DPP-4i are associated with a slower rate of cognitive decline compared to metformin with TZD in patients with AD and T2DM. These findings provide novel evidence for the long-term cognitive benefits of specific antidiabetic therapies and offer valuable insights for clinical decision-making in this dual-affected population.

24 March 2026 in Journal of Affective Disorders Reports
Verified
Journal Article
Open access
HZHongyi Zou
Hongyi Zou
CJChen Jiang
Chen Jiang
XQXIGUANG QI
XIGUANG QI
OMOshin Miranda
Oshin Miranda
TXTianyi Xie
Tianyi Xie
LiRong WangLiRong Wang
LiRong Wang
Due to its long-term effectiveness in weight control and cost-efficiency, bariatric metabolic surgery (BMS) has emerged as a promising treatment option for patients with severe obesity. However, its impact on certain mental health disorders remains unclear. This study aimed to utilize a deep learning (DL) model, DeepBiomarker2, which integrates social determinants of health (SDoH) and electronic health records (EHR), to identify clinical features associated with new-onset anxiety disorder following BMS. We conducted a case-control study using longitudinal EHR data from the University of Pittsburgh Medical Center (Jan 2004–Oct 2019) on patients who underwent bariatric surgery. DeepBiomarker2, a DL model integrating diagnoses, medications, lab tests, and neighborhood socioeconomic status, predicted new-onset anxiety. Perturbation-based contribution analysis identified key predictive features. A total of 14,856 eligible patients who underwent BMS without a prior history of anxiety disorder were identified. DL models outperformed traditional logistic regression in predicting post-BMS anxiety, yielding area under the curve (AUC) values exceeding 0.89. Key features associated with post-BMS anxiety included abnormal urine and blood lab results, opioid and psychiatric medication use, frequent emergency department (ED) visits, and pre-existing mental health conditions. Potential protective indicators included omega-3 fatty acids, vitamin B12, calcium citrate, and pravastatin. Inclusion of nSES data led to marginal improvements in model performance. Our DL models successfully identified clinical features potentially associated with new-onset anxiety following BMS, offering valuable insights to support early intervention and personalized mental health strategies for postoperative care.